Literature DB >> 25479818

Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options.

Stephan Rosenkranz1.   

Abstract

Pulmonary hypertension (PH) is a common phenomenon that may occur as a consequence of various diseases (e.g., heart failure, chronic lung diseases, and pulmonary embolism), as a distinct disease of the small pulmonary arterioles, or a combination of both. Independently from the origin, PH has important impact on patient´s symptoms and life expectancy. The establishment of an exact diagnosis and classification, as well as the understanding of the hemodynamic interrelations, provides the basis for often challenging treatment decisions. Recently, the 5th World Symposium on PH took place in Nice, France, where important standards and definitions were specified. Furthermore, the results of recent phase III trials have led to the approval of new targeted therapies. The most relevant developments including the rating of novel treatment options are summarized in this article.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25479818     DOI: 10.1007/s00392-014-0765-4

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  56 in total

Review 1.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

2.  Riociguat for the treatment of pulmonary arterial hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

3.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.

Authors:  William T Abraham; Philip B Adamson; Robert C Bourge; Mark F Aaron; Maria Rosa Costanzo; Lynne W Stevenson; Warren Strickland; Suresh Neelagaru; Nirav Raval; Steven Krueger; Stanislav Weiner; David Shavelle; Bradley Jeffries; Jay S Yadav
Journal:  Lancet       Date:  2011-02-19       Impact factor: 79.321

4.  Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension.

Authors:  Bart G Boerrigter; Harm J Bogaard; Pia Trip; Herman Groepenhoff; Heleen Rietema; Sebastiaan Holverda; Anco Boonstra; Pieter E Postmus; Nico Westerhof; Anton Vonk-Noordegraaf
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

5.  Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension.

Authors:  Christian Gerges; Mario Gerges; Marie B Lang; Yuhui Zhang; Johannes Jakowitsch; Peter Probst; Gerald Maurer; Irene M Lang
Journal:  Chest       Date:  2013-03       Impact factor: 9.410

6.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

7.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

8.  Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

Authors:  Karen M Olsson; Marion Delcroix; H Ardeschir Ghofrani; Henning Tiede; Doerte Huscher; Rudolf Speich; Ekkehard Grünig; Gerd Staehler; Stephan Rosenkranz; Michael Halank; Matthias Held; Tobias J Lange; Juergen Behr; Hans Klose; Martin Claussen; Ralf Ewert; Christian F Opitz; C Dario Vizza; Laura Scelsi; Anton Vonk-Noordegraaf; Harald Kaemmerer; J Simon R Gibbs; Gerry Coghlan; Joanna Pepke-Zaba; Uwe Schulz; Matthias Gorenflo; David Pittrow; Marius M Hoeper
Journal:  Circulation       Date:  2013-09-30       Impact factor: 29.690

9.  Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure.

Authors:  Wayne L Miller; Diane E Grill; Barry A Borlaug
Journal:  JACC Heart Fail       Date:  2013-08-05       Impact factor: 12.035

Review 10.  Genetics and genomics of pulmonary arterial hypertension.

Authors:  Florent Soubrier; Wendy K Chung; Rajiv Machado; Ekkehard Grünig; Micheala Aldred; Mark Geraci; James E Loyd; C Gregory Elliott; Richard C Trembath; John H Newman; Marc Humbert
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

View more
  16 in total

Review 1.  [Telemonitoring and pulmonary artery pressure-guided treatment of heart failure].

Authors:  C E Angermann; S Rosenkranz
Journal:  Internist (Berl)       Date:  2018-10       Impact factor: 0.743

2.  Key inflammatory pathways underlying vascular remodeling in pulmonary hypertension.

Authors:  E M Berghausen; L Feik; M Zierden; M Vantler; S Rosenkranz
Journal:  Herz       Date:  2019-04       Impact factor: 1.443

3.  Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study.

Authors:  Felix Gerhardt; Daniel Dumitrescu; Carina Gärtner; Ralf Beccard; Thomas Viethen; Tilmann Kramer; Stephan Baldus; Martin Hellmich; Eckhard Schönau; Stephan Rosenkranz
Journal:  Heart       Date:  2017-01-18       Impact factor: 5.994

Review 4.  BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.

Authors:  Mar Orriols; Maria Catalina Gomez-Puerto; Peter Ten Dijke
Journal:  Cell Mol Life Sci       Date:  2017-04-26       Impact factor: 9.261

5.  Pentaerythritol Tetranitrate In Vivo Treatment Improves Oxidative Stress and Vascular Dysfunction by Suppression of Endothelin-1 Signaling in Monocrotaline-Induced Pulmonary Hypertension.

Authors:  Sebastian Steven; Matthias Oelze; Moritz Brandt; Elisabeth Ullmann; Swenja Kröller-Schön; Tjebo Heeren; Lan P Tran; Steffen Daub; Mobin Dib; Dirk Stalleicken; Philip Wenzel; Thomas Münzel; Andreas Daiber
Journal:  Oxid Med Cell Longev       Date:  2017-02-28       Impact factor: 6.543

6.  Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial.

Authors:  Robert P Baughman; Oksana A Shlobin; Rohit Gupta; Peter J Engel; Jeffrey I Stewart; Elyse E Lower; Franck F Rahaghi; Joyce Zeigler; Steven D Nathan
Journal:  Chest       Date:  2021-08-04       Impact factor: 9.410

Review 7.  Left ventricular heart failure and pulmonary hypertension.

Authors:  Stephan Rosenkranz; J Simon R Gibbs; Rolf Wachter; Teresa De Marco; Anton Vonk-Noordegraaf; Jean-Luc Vachiéry
Journal:  Eur Heart J       Date:  2015-10-27       Impact factor: 29.983

8.  Perioperative management of patients with severe pulmonary hypertension in major orthopedic surgery: experience-based recommendations.

Authors:  Hans-Jürgen Seyfarth; Jochen Gille; Armin Sablotzki; Stefan Gerlach; Michael Malcharek; Andreas Gosse; Ralf H Gahr; Elke Czeslick
Journal:  GMS Interdiscip Plast Reconstr Surg DGPW       Date:  2015-01-14

9.  MnTBAP Reverses Pulmonary Vascular Remodeling and Improves Cardiac Function in Experimentally Induced Pulmonary Arterial Hypertension.

Authors:  Maria Catalina Gomez-Puerto; Xiao-Qing Sun; Ingrid Schalij; Mar Orriols; Xiaoke Pan; Robert Szulcek; Marie-José Goumans; Harm-Jan Bogaard; Qian Zhou; Peter Ten Dijke
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

10.  Effects of Bcl-2/Bcl-xL Inhibitors on Pulmonary Artery Smooth Muscle Cells.

Authors:  Vladyslava Rybka; Yuichiro J Suzuki; Nataliia V Shults
Journal:  Antioxidants (Basel)       Date:  2018-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.